PLRX
Pliant Therapeutics Inc

1,715
Mkt Cap
$92.17M
Volume
1.68M
52W High
$15.80
52W Low
$1.10
PE Ratio
-0.52
PLRX Fundamentals
Price
$1.56
Prev Close
$1.50
Open
$1.51
50D MA
$1.59
Beta
1.42
Avg. Volume
954,758.57
EPS (Annual)
-$3.47
P/B
0.46
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pliant Therapeutics (NASDAQ:PLRX) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded shares of Pliant Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of...
MarketBeat·13d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·9mo ago
News Placeholder
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation...
PR Newswire·9mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·9mo ago
News Placeholder
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pliant Therapeutics, Inc. (Pliant or the Company) (NASDAQ...
Business Wire·9mo ago
News Placeholder
Buy Rating Affirmed for Pliant Therapeutics Amid Progress in IPF Treatment Trials
Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Pliant Therapeutics (PLRX Research Report), boosting the price target to $38.00. Ed...
TipRanks Financial Blog·1y ago
News Placeholder
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung collagen, improved FVC, and cough severity, signaling potential fibrosis...
Benzinga·2y ago
News Placeholder
Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Globe Newswire·2y ago
News Placeholder
Pliant Therapeutics (PLRX, $14.81) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024
This indicator may be signaling that PLRX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·2y ago

Latest PLRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.